Sequencing of Radium-223 and Lutetium-177 Vipivotide Tetraxetan: Maximizing the Benefit of Systemic Targeted Radiation Therapy in Metastatic Castration-Resistant Prostate Cancer
As the majority of men with metastatic castration-resistant prostate cancer first present with bone-only metastases, they may be treated initially with radium-223, while still remaining eligible to benefit from chemotherapy and <sup>177</sup>Lu-PSMA upon subsequent progression of skeletal metastatic disease and/or the emergence of lymph node or visceral metastases. Graphical abstract available for this article.
Authors
- Ralph J. Hauke (ORCID: https://orcid.org/0000-0002-0243-7279)
- Samuel A. Mehr (ORCID: https://orcid.org/0000-0002-9400-7718)
Institutions
- Nebraska Medical Center (US)
- Nebraska Cancer Specialists (US)
- MRIGlobal (US)
Publication Details
- Journal
- Oncology and Therapy
- Published
- 2025-10-08
- DOI
- https://doi.org/10.1007/s40487-025-00377-9
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00